Tumor‐infiltrating immune cells predict the response to somatostatin receptor ligands only in somatotropinomas naïve to medical therapy

Documenti analoghi

• Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors
  di: Giulia Santo, et al.
  Pubblicazione: (2025)
• Optimal follow‐up with somatostatin receptor PET / CT imaging in patients with small intestinal neuroendocrine tumours
  di: Håkan Ohlsson, et al.
  Pubblicazione: (2024)
• Screening and surveillance practices for Multiple Endocrine Neoplasia type 1‐related Neuroendocrine Tumours in European Neuroendocrine Tumor Society Centers of Excellence ( ENETS CoE )—An ENETS MEN1 task force questionnaire study
  di: Carolina R. C. Pieterman, et al.
  Pubblicazione: (2024)
• Prevalence of metastases outside the liver and abdominal lymph nodes on 68 Ga‐DOTATOC‐PET / CT in patients with small intestinal and pancreatic neuroendocrine tumours
  di: Maria Wedin, et al.
  Pubblicazione: (2024)
• PRRT in high‐grade digestive neuroendocrine neoplasms ( NET G3 and NEC )
  di: Halfdan Sorbye, et al.
  Pubblicazione: (2024)